Debt rising as profit falls
Total debt rose 180.1% while net profit fell 26.7% — worth checking how the balance sheet is being funded.
Importance 77 / 95 · financial health
The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.
Total debt rose 180.1% while net profit fell 26.7% — worth checking how the balance sheet is being funded.
Importance 77 / 95 · financial health
Revenue grew 2.2% but profit declined 26.7%, so the company kept less of each rupee of revenue as profit.
Importance 73 / 95 · growth
EBITDA margin dropped 5.0 percentage points in a single year, from 29.0% to 24.0% — worth investigating.
Importance 68 / 95 · anomaly
Classified by the exchange under Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals.
Peer set used on this page: 12 pharmaceuticals.
Revenue grew 6.7% a year over 4 years, from ₹21,763 cr in FY2022 to ₹28,163 cr in FY2026. Net profit grew 11.0% a year over the same period.
Revenue grew 2.2% but profit declined 26.7%, so the company kept less of each rupee of revenue as profit.
Rule PROFIT_SLOWER_THAN_REVENUE
Over 4 years profit compounded at 11.0% a year while revenue compounded at 6.7% a year — though FY2024 saw a one-off step-change of 47% (a merger, restructuring or a recovery off a low base), so the compounding is uneven.
Net profit fell 26.7% year on year (FY2025 → FY2026).
Revenue has compounded at 6.7% a year over 4 years (₹21,763 → ₹28,163) — steady rather than rapid.
In Q2 FY27 (Jul–Sep 2026), revenue was ₹7,404 cr (down 2.4% on the same quarter last year) and net profit ₹852 cr (down 37.1%).
Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.
Q2 FY27 net profit was ₹852 cr, down 37.1% from ₹1,353 cr a year earlier.
Rule QTR_PROFIT_GROWTH_YOY
Q2 FY27 net profit declined 37.1% while revenue declined 2.4% vs the same quarter last year — a gap of 34.6 percentage points.
Rule QTR_PROFIT_VS_REVENUE_GROWTH
Q2 FY27 EBIT was ₹1,194 cr, down 36.0% from ₹1,867 cr a year earlier.
Rule QTR_OPERATING_PERFORMANCE_CHANGE_YOY
| Quarter | Revenue | YoY | Net profit | YoY | Net margin |
|---|---|---|---|---|---|
| Q3 FY25 | 7,073 | +7.1% | 1,575 | +47.4% | 22.3% |
| Q4 FY25 | 6,730 | +9.2% | 1,214 | +30.3% | 18.0% |
| Q1 FY26 | 6,957 | +3.9% | 1,292 | +9.9% | 18.6% |
| Q2 FY26 | 7,589 | +7.6% | 1,353 | +3.7% | 17.8% |
| Q3 FY26 | 7,074 | +0.0% | 674 | −57.2% | 9.5% |
| Q4 FY26 | 6,541 | −2.8% | 543 | −55.3% | 8.3% |
| Q1 FY27 | 7,119 | +2.3% | 786 | −39.2% | 11.0% |
| Q2 FY27 | 7,404 | −2.4% | 852 | −37.1% | 11.5% |
Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters
EBITDA margin was 24.0% in FY2026, against 22.2% in FY2022. ROE was 11.7% and ROCE 16.8% in FY2026.
ROE declined from 18.1% to 11.7% year on year.
Rule ROE_DETERIORATED_YOY
EBITDA margin has ranged from 22.2% to 29.0% over 4 years and sits at 24.0% now.
It had little or no debt in FY2026 (debt-to-equity 0.01x). Operating cash flow was 1.02x net profit.
Total debt rose 180.1% while net profit fell 26.7% — worth checking how the balance sheet is being funded.
Rule DEBT_UP_EARNINGS_DOWN
Net worth compounded at 13.1% a year over 4 years (₹21,117 → ₹34,520).
Free cash flow has been positive in 5 of the last 5 years.
Within its 12-company Pharmaceuticals peer group, it ranks 9 of 12 on return on equity and 9 of 12 on EBITDA margin. Its P/E of 40.1 compares with a peer median of 45.3.
Ranked against 12 pharmaceuticals (FY2026, consolidated).
CIPLA · 12th of 12 · set median 14.8%
CIPLA · 9th of 12 · set median 28.7%
CIPLA · 9th of 12 · set median 14.4%
CIPLA · 4th of 12 · set median 45.3×
Trades at 3.31× book — 30% below the pharmaceuticals median of 4.74×.
Rule PB_BELOW_PEERS
On the trailing twelve months. Last full year: P/E 29.6× · P/S 3.9× · ROE 11.7%. TTM and full-year profit and EBITDA differ by more than 15% — a one-off in a recent quarter is moving the trailing figure; weigh it against the full year.
The share price is down 7.5% over 1 year, up 12.9% over 3 years (4.1% a year) and up 58.6% over 5 years (9.7% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is 7.6% below its 52-week high.
Over 4 years profit compounded at 11.0% a year while the stock returned 4.1% a year — the FY2022 base was somewhat depressed, so part of this is recovery rather than trend.
Rule STOCK_LAGGED_EARNINGS · rebound
Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.
Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.
The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 21,763 | 22,753 | 25,774 | 27,548 | 28,163 |
| Total income | 22,044 | 23,229 | 26,521 | 28,409 | 29,045 |
| EBITDA | 4,834 | 5,502 | 7,038 | 7,990 | 6,765 |
| Profit before tax | 3,493 | 4,038 | 5,702 | 6,821 | 5,224 |
| Net profit | 2,547 | 2,833 | 4,154 | 5,269 | 3,862 |
| EPS (₹) | 31.2 | 34.7 | 51.0 | 65.3 | 48.0 |
| Net worth | 21,117 | 23,714 | 26,802 | 31,289 | 34,520 |
| Total debt | 824 | 520 | 247 | 92 | 258 |
| Operating cash flow | 3,326 | 3,238 | 4,134 | 5,005 | 3,940 |
| Free cash flow | 2,813 | 2,427 | 3,070 | 3,868 | 2,364 |
| Ratio | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Growth | |||||
| Revenue growth YoY | — | 4.5 | 13.3 | 6.9 | 2.2 |
| Profit growth YoY | — | 11.2 | 46.6 | 26.9 | -26.7 |
| Profitability | |||||
| EBITDA margin % | 22.2 | 24.2 | 27.3 | 29.0 | 24.0 |
| Net margin % | 11.6 | 12.2 | 15.7 | 18.5 | 13.3 |
| Return on equity % | 12.1 | 12.6 | 16.4 | 18.1 | 11.7 |
| Return on capital % | 17.2 | 18.8 | 23.3 | 23.6 | 16.8 |
| Leverage & cash | |||||
| Debt to equity | 0.04 | 0.02 | 0.01 | 0.00 | 0.01 |
| Cash flow ÷ profit | 1.31 | 1.14 | 1.00 | 0.95 | 1.02 |
| Current ratio | 2.99 | 3.34 | 3.70 | 4.24 | 3.44 |